Inspire Medical Systems Inc
INSP
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
309.6% upsideUndervalued by 309.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.19 Billion |
|---|---|
| Enterprise Value | $1.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.95 |
| Beta | 0.83 |
| Outstanding Shares | 28,700,525 |
Return
| Return on Equity | 16.55% |
|---|---|
| Return on Assets | 14.39% |
| Return on Invested Capital | 5.77% |
Valuation & Multiples
| P/E Ratio | 9.05 |
|---|---|
| PEG | -1.9 |
| Price to Sales | 1.31 |
| Price to Book Ratio | 1.5 |
| Enterprise Value to Revenue | 1.23 |
| Enterprise Value to EBIT | 23.68 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.5313▲ 245.45% |
|---|---|
| Total Calls | 83,200▼ 80.70% |
| Total Puts | 293,800▼ 36.69% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 120.47%▲ 3.40% |
|---|---|
| Total Invested | $1.80B▼ 42.43% |
| Investors Holding | 310▼ 55.00% |
ESG Score
No data
About Inspire Medical Systems Inc
CEO: Timothy Herbert Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and onl...
Relevant Senate Committees
Controls taxation, trade, and entitlement spending, including Medicare pricing and reimbursement policies, which are critical revenue drivers and market access factors for INSP's medical device.
Directly allocates federal spending, including healthcare programs (e.g., Medicare/Medicaid through subcommittees), which can significantly impact reimbursement and market access for INSP's device.
Directly regulates the FDA, which is critical for medical device approval, oversight, and ongoing market access for INSP's proprietary therapy.